Switch studies in virologically suppressed patients

Switch PI/R to ETR
Etraswitch Study
Original article : PLoS One. 2014 Feb 4;9(2):e84676 – P Echeverria
Last update : 07/09/2015

Dr Anton Pozniak
Chelsea and Westminster Hospital
London, UK

  • Switch from a PI-based regimen to a once-daily combination based on ETR maintained undetectable VL during 48 weeks in virologically suppressed HIV-infected patients while lipid profile and patient satisfaction improved significantly

Design


* 4 x 100 mg pills dissolved in water

Objective

  • Primary Endpoint: % HIV RNA < 50 c/mL, on-treatment and ITT, M=F
  • Secondary endpoints: change in CD4, CD8, metabolic parameters (lipids and glucose), safety, patient satisfaction

Baseline characteristics and disposition


Virologic and immunologic outcomes at W48

  • No difference in CD4 change

Metabolic parameters and satisfaction

Safety

  • No Grade3-4 clinical adverse events
  • No significant changes in liver enzymes in either group, no Grade 3-4 elevations

 

Back to Table of Contents

     
     
     
Copyright AEI 2017 | Links | Contact | Faculty and Disclosure | Terms of use aei